Radionuclide Ventriculography

Overview¶

Radionuclide ventriculography evaluates ventricular function by tracking a radiolabeled blood pool through the cardiac cycle.

Techniques¶

MUGA uses Tc-99m–labeled red blood cells with ECG-gated imaging over several hundred cardiac cycles.

LVEF Calculation¶

Counts must be corrected for background activity.

Strengths¶

• Highly reproducible LVEF
• Less dependent on acoustic windows
• Useful for serial measurements
• Limited geometric assumptions
• Can assess regional wall motion

Limitations¶

• Ionizing radiation
• Limited structural and valvular information
• Poorer temporal resolution than echocardiography or CMR
• Chamber overlap
• Requires a stable rhythm for accurate gating
• Does not directly measure myocardial perfusion

Sources of Error¶

• Atrial fibrillation or frequent ectopy
• Incorrect R-wave detection
• Inadequate red-cell labeling
• Incorrect ventricular ROI
• Poor background subtraction
• Left atrial or RV overlap
• Inconsistent positioning between serial studies

Cardio-Oncology¶

MUGA has historically been used for serial LVEF monitoring during cardiotoxic therapy because of its reproducibility. Echocardiography with strain is now generally preferred, but MUGA remains useful when echo images are inadequate or reproducible serial EF measurement is required.

Use the same modality when possible for longitudinal comparison.

Board Pearls¶

• MUGA measures counts, not ventricular volumes directly.
• Background subtraction is required for accurate EF.
• Arrhythmias reduce gating accuracy.
• First-pass imaging is better suited to RV transit and shunt evaluation.
• MUGA is reproducible but provides little information about valves or myocardial tissue.

References¶

• ASNC Cardio-Oncology Information Statement
• SNMMI Procedure Standards